Eli Lilly and Company / LLY

Equity | Generated Nov 25, 2026 11:32 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,395.44	-12.15 -0.86%	-/-	$1,407.59

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Nov 25, 2026 11:32 PM EST**

JW Intelligence Report

Complete | 3 of 3 sections | Nov 25, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
74.0 / 100	Constructive	high	44 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,388.00	$1,460.00	$1,355.00	81 / 100

Options stance	**bullish**
Tail-risk safety	**44 / 100**
JW Rank data coverage / as of	**100.0% | Nov 25, 2026 6:50 PM EST**

Key insight

LLY Option Market Implies Continued Upside Potential

Market read

The LLY option market displays a bullish outlook, with implied volatility suggesting expectations for continued price movement. The term structure is in contango, indicating higher IV for longer-dated options, which could reflect anticipation of future catalysts or earnings events. While recent news includes both positive and negative factors, the overall sentiment leans cautiously bullish.

Strategy context

LLY's recent earnings beat and raised guidance have fueled optimism. However, concerns about GLP-1 safety and competition remain.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 25, 2026 2:20 PM EST**

Short-term scenario

Cautious long / buy-the-dip bias over 1-3 weeks, not a chase. Prefer weakness toward support rather than strength into resistance. Uncertainty is high: valuation is elevated, momentum has cooled, and headline risk (pricing, competition, GLP-1 safety litigation, deal integration) can move the stock quickly. This is not a recommendation to buy or sell.

Three-month outlook

Constructive but limited-upside base case if volume growth holds. Raised 2026 guidance, GLP-1 scale, and catalysts (Dec 7 Innovation Day, oral/retatrutide updates, oncology narrative) support a grind toward the mid-$1,400s to low-$1,500s. Consensus targets already imply only modest upside, so multiple compression is a real risk. Downside scenarios include pricing pressure, competitive or safety headlines, or a guidance miss, which could retest the 50-day area near $1,280. Uncertainty is elevated and the path is likely choppy rather than a straight-line rally.

Market sentiment

Recent high-signal posts are sparse and mixed. One sentiment aggregator cited roughly 71% bullish / 14% bearish. Some traders still treat LLY as a bullish chart and cite the Hims partnership and obesity franchise; at least one short-term trader listed it as ‘stay away’ on Nov 25. Broader discussion is constructive on GLP-1 volume leadership but repeatedly flags valuation, pricing, and competition. Sentiment is cautiously bullish, not euphoric.

Supporting evidence


The front-month ATM implied volatility is 27.92%, suggesting market participants expect significant price swings in the near term. | The skew is put-demand elevated, indicating a higher demand for put options, potentially reflecting some hedging or bearish sentiment towards potential downside risk. | The term structure slopes upwards, with longer-dated IV exceeding shorter-dated IV, hinting at expectations for continued volatility and potential upside in the future.

Risk watch

FDA class warning on possible GLP-1 vision-loss risk could impact investor sentiment and stock price. | Competition in the weight-loss drug market could pressure pricing and market share.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Below MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD decelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**52.27 / 56.21 / 57.90**
RSI velocity	**2.24**
MACD line / signal / histogram	**27.27 / - / 37.69**
MACD acceleration	**-1.99**
Stochastic K / D	**38.67 / 27.19**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Below institutional MVWAP | Accumulation bias**
Institutional flow	**2.38**
20-day MVWAP	**$1,399.39**
Price vs 20-day MVWAP	**-0.28%**
Daily reference VWAP	**$1,391.99**
Price vs daily reference	**+0.25%**
Volume	**1.64M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**5.25**
20-day / 200-day SMA	**$1,399.66 / $1,123.08**
Bollinger range	**$1,337.76 - $1,461.57**
Bollinger position	**0.440**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
35 / 100	**46 / 100**	**115.97**	**139.16**

Market regime	**Calm**
Tail-risk regime	**HIGH TAIL RISK**
Term structure	**contango**
Term slope	**+7.83 pts**
Skew read	**PUT DEMAND ELEVATED**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 25, 2026 2:54 PM EST**
Options data quality	**Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration



Upward-sloping ATM volatility term structure


EXPIRATION	DTE	ATM IV	STATE
2026-11-27	2	27.9%	-
2026-12-04	9	33.5%	-
2026-12-11	16	35.8%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short $1,380.00 | Long $1,375.00 | Width $5.00 | Net credit $0.98



Max profit $98.00 | Max loss -$402.00 | Break-even $1,379.02 | Per contract at expiry

Bear Call Spread reference

Short $1,417.50 | Long $1,420.00 | Width $2.50 | Net credit $0.83



Max profit $83.00 | Max loss -$167.00 | Break-even $1,418.33 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2027-02-03**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**28.20**
VVIX	**115.97**
SKEW index	**139.16**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**142**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	**142**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The LLY option market displays a bullish outlook, with implied volatility suggesting expectations for continued price movement. The term structure is in contango, indicating higher IV for longer-dated options, which could reflect anticipation of future catalysts or earnings events. While recent news includes both positive and negative factors, the overall sentiment leans cautiously bullish.

Options context

LLY Option Market Implies Continued Upside Potential

Wheel context

LLY's recent earnings beat and raised guidance have fueled optimism. However, concerns about GLP-1 safety and competition remain.

Observed evidence

The front-month ATM implied volatility is 27.92%, suggesting market participants expect significant price swings in the near term. | The skew is put-demand elevated, indicating a higher demand for put options, potentially reflecting some hedging or bearish sentiment towards potential downside risk. | The term structure slopes upwards, with longer-dated IV exceeding shorter-dated IV, hinting at expectations for continued volatility and potential upside in the future.

Principal risks to monitor

FDA class warning on possible GLP-1 vision-loss risk could impact investor sentiment and stock price. | Competition in the weight-loss drug market could pressure pricing and market share.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.32T	**48.01**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.38**

52-week range

$850.51 - $1,475.25

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**31.5%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	lilly.com

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Nov 23, 2026 1:31 PM EST

Covered Call | 2026-12-04

At signal $1,363.33 | Current $1,395.44

SHORT **Option $1,400.00 B $15.60 / A $18.00**

Conservative | CR $16.80

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$42.65**
ATR as % of price	**3.1%**
Volatility environment	**medium**
Current IV	**34.0%**
IV rank	**33 / 100**
IV percentile	**44 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 25, 2026 6:32 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**88 / 100**
Trend health	**92 / 100**
Momentum health	**98 / 100**
Volatility health	**64 / 100**
Structure health	**94 / 100**
Earnings risk / date	**low | 2027-02-03**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,399.66 / $1,281.96 / $1,123.08**
EMA (9 / 21)	**$1,388.32 / $1,371.66**
Bollinger upper / middle / lower	**$1,461.57 / $1,399.66 / $1,337.76**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.440**
True high / low	**$1,412.99 / $1,370.76**
5-day true high / low	**$1,415.00 / $1,341.46**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	5.251	**-**
SMA50	5.015	**-**
MVWAP20	2.375	**-**
MACD	-1.989	**-**
RSI	2.238	**-**
Volume	-103054.330	**-**
ATR	0.074	**-**
T1	-	**28.94 / 1396.61 / 1415.00 / 1364.60**
T2	-	**29.09 / 1393.95 / 1381.65 / 1344.00**
T3	-	**33.24 / 1392.26 / 1372.05 / 1341.76**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,398.48**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 25, 2026 2:54 PM EST**
Options data coverage	**88.9%**
SKEW regime	**NORMAL TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-11-27 | 2 DTE**
Front at-the-money IV	**27.9%**
25-delta skew	**5.01**
Put / Call 25-delta	**$1,380.00 Delta -0.266 / $1,417.50 Delta 0.247**
Median option bid/ask spread	**23.4%**
Bid/ask spread	**-**
Contracts observed / quoted	**142 / 142**

Price context

Last Price: 1,398.48 | Bid: 1,397.95 | Ask: 1,398.83 | Previous Close: 1,407.59 | Change: -9.11 | Daily change: -0.65% | Update Time: 2026-11-25T14:54:30.438800-05:00 | Latest History Date: 2026-11-25 | Latest History Price: 1,398.48

Historical context

Trading-day sample: 60 sessions | First Date: 2026-09-02 | Latest Date: 2026-11-25 | Latest Price: 1,398.48 | Max Drawdown 60d Percent: -6.68%

Fundamental context

Current Iv Percent: 34.29% | Iv Rank: 34.65 | Iv Percentile: 46.22 | Next Earnings Date: 2027-02-03 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 25, 2026 11:32 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**